2022-04-01T17:46:20Z
2022-04-01T17:46:20Z
2021-02-10
2022-04-01T17:46:21Z
Breast cancer (BC) is a leading cause of death between women. Mortality is significantly raised due to drug resistance and metastasis, while personalized treatment options are obstructed by the limitations of conventional biopsy follow-up. Lately, research is focusing on circulating biomarkers as minimally invasive choices for diagnosis, prognosis and treatment monitoring. Circulating cell-free DNA (ccfDNA) is a promising liquid biopsy biomaterial of great potential as it is thought to mirror the tumor's lifespan; however, its clinical exploitation is burdened mainly by gaps in knowledge of its biology and specific characteristics. The current review aims to gather latest findings about the nature of ccfDNA and its multiple molecular and biological characteristics in breast cancer, covering basic and translational research and giving insights about its validity in a clinical setting.
Artículo
Versión publicada
Inglés
Càncer de mama; Pronòstic mèdic; ADN; Biòpsia; Marcadors bioquímics; Breast cancer; Prognosis; DNA; Biopsy; Biochemical markers
MDPI
Reproducció del document publicat a: https://doi.org/10.3390/cancers13040728
Cancers, 2021, vol. 13, num. 4, p. 728
https://doi.org/10.3390/cancers13040728
cc-by (c) Panagopoulou, Maria et al., 2021
https://creativecommons.org/licenses/by/4.0/